The estimated Net Worth of Sean Maduck is at least $7.05 Milion dollars as of 13 May 2024. Mr. Maduck owns over 50,000 units of Corcept Therapeutics Inc stock worth over $4,807,142 and over the last 7 years he sold CORT stock worth over $0. In addition, he makes $2,241,290 as Senior Vice President - Commercial at Corcept Therapeutics Inc.
Sean has made over 27 trades of the Corcept Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 50,000 units of CORT stock worth $194,000 on 13 May 2024.
The largest trade he's ever made was exercising 70,000 units of Corcept Therapeutics Inc stock on 12 December 2018 worth over $189,000. On average, Sean trades about 14,591 units every 52 days since 2018. As of 13 May 2024 he still owns at least 135,222 units of Corcept Therapeutics Inc stock.
You can see the complete history of Mr. Maduck stock trades at the bottom of the page.
Sean Maduck serves as Senior Vice President - Commercial of the Company. He has served as our Senior Vice President, Commercial since April 2016. Prior to that, he served as our Vice President, Sales & Marketing. Mr. Maduck joined Corcept in 2012, bringing to the company 12 years of pharmaceutical, biotechnology and management experience. From 2002 to 2012, he held positions in the Finance, Portfolio Planning, and Commercial functions at Genentech. Prior to Genentech, he was an investment banking analyst at W.R Hambrecht + Company. He currently serves on the Board of Directors of the Cancer Support Community – San Francisco Bay Area. Mr. Maduck earned an A.B. from Dartmouth College, a B.E. in Biomedical Engineering from the Thayer School of Engineering at Dartmouth College, and a Masters in Management from the Stanford Graduate School of Business.
As the Senior Vice President - Commercial of Corcept Therapeutics Inc, the total compensation of Sean Maduck at Corcept Therapeutics Inc is $2,241,290. There are 3 executives at Corcept Therapeutics Inc getting paid more, with Joseph Belanoff having the highest compensation of $4,958,970.
Sean Maduck is 43, he's been the Senior Vice President - Commercial of Corcept Therapeutics Inc since 2016. There are 16 older and 2 younger executives at Corcept Therapeutics Inc. The oldest executive at Corcept Therapeutics Inc is George Baker, 77, who is the Independent Director.
Sean's mailing address filed with the SEC is C/O CORCEPT THERAPEUTICS INCORPORATED, 101 REDWOOD SHORES PARKWAY, REDWOOD CITY, CA, 94065.
Over the last 21 years, insiders at Corcept Therapeutics Inc have traded over $107,318,493 worth of Corcept Therapeutics Inc stock and bought 71,912,273 units worth $127,133,071 . The most active insiders traders include Patrick G Enright, Allen Andersson a Ventures, Llc Paperboy. On average, Corcept Therapeutics Inc executives and independent directors trade stock every 14 days with the average trade being worth of $8,010,233. The most recent stock trade was executed by William Guyer on 3 September 2024, trading 10,000 units of CORT stock currently worth $216,500.
leading the field in the discovery of drugs that modulate the effects of cortisol the adverse effects of excess cortisol have been corcept’s focus since the company’s inception. abnormal levels and release of cortisol play a role in a variety of metabolic, oncological, and psychiatric diseases, and we are currently studying a new generation of compounds that may mitigate the effects of excess cortisol. in addition to our work with mifepristone, we have developed over 300 proprietary molecules, advancing the most promising of these to the clinic to see if they can mitigate the effects of excess cortisol and the serious, sometimes life-threatening conditions that may result. all of these compounds competitively block the glucocorticoid receptor (gr), but not the progesterone receptor. scientific literature suggests that competitive gr antagonism may have a role in treating many conditions, including post-traumatic stress disorder, mild cognitive impairment, alzheimer’s disease, alcoholis
Corcept Therapeutics Inc executives and other stock owners filed with the SEC include: